Yuan Sun - HANSOH PHARMAC Executive Director
| 3KY Stock | EUR 2.16 0.06 2.70% |
Insider
Yuan Sun is Executive Director of HANSOH PHARMAC HD 00001 since 2015.
| Age | 32 |
| Tenure | 9 years |
| Phone | 86 21 3177 3517 |
| Web | http://www.hspharm.com |
HANSOH PHARMAC Management Efficiency
The company has return on total asset (ROA) of 0.063 % which means that it generated a profit of $0.063 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1366 %, meaning that it generated $0.1366 on every $100 dollars invested by stockholders. HANSOH PHARMAC's management efficiency ratios could be used to measure how well HANSOH PHARMAC manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Shinichi Murayama | Hisamitsu Pharmaceutical Co | 56 | |
| R Hoover | Elanco Animal Health | 73 | |
| Christopher OReilly | Takeda Pharmaceutical | N/A | |
| Yonghui Wu | CanSino Biologics | N/A | |
| Kai Beckmann | Merck Company | 58 | |
| Haruhiko Hirate | Takeda Pharmaceutical | 66 | |
| Nobuo Tsutsumi | Hisamitsu Pharmaceutical Co | 59 | |
| Constantin Fest | Merck Company | 46 | |
| Carl McMillian | Elanco Animal Health | 51 | |
| Matthias Heinzel | Merck Company | 56 | |
| Koin Toda | Tsumura Co | N/A | |
| Dean Li | Merck Company | N/A | |
| Michael Harrington | Elanco Animal Health | 56 | |
| Larbi Lier | Elanco Animal Health | N/A | |
| Qiang Xu | CanSino Biologics | 50 | |
| Mitsuru Nakata | Tsumura Co | N/A | |
| David Kinard | Elanco Animal Health | 56 | |
| Ryuji Takasaki | Tsumura Co | N/A | |
| Kosuke Sugiyama | Hisamitsu Pharmaceutical Co | 71 | |
| Susumu Adachi | Tsumura Co | 60 | |
| Marcela Kirberger | Elanco Animal Health | 56 | |
Management Performance
| Return On Equity | 0.14 | |||
| Return On Asset | 0.063 |
HANSOH PHARMAC HD Leadership Team
Elected by the shareholders, the HANSOH PHARMAC's board of directors comprises two types of representatives: HANSOH PHARMAC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HANSOH. The board's role is to monitor HANSOH PHARMAC's management team and ensure that shareholders' interests are well served. HANSOH PHARMAC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HANSOH PHARMAC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Min Hu, Vice President | ||
| Shengli Zhong, Vice President Joint Company Secretary | ||
| Huijuan Zhong, Chief Executive Officer, Executive Chairlady of the Board | ||
| Chuanhe Xu, Senior Vice President | ||
| Sheung Chan, Non-Executive Independent Director | ||
| Rudi Bao, Senior Vice President | ||
| Chunhua Zhong, Senior Vice President | ||
| Guoqiang Lin, Non-Executive Independent Director | ||
| Dongtao Yang, Non-Executive Independent Director | ||
| Yuan Sun, Executive Director | ||
| Cuifang Ma, Non-Executive Director | ||
| Gongzheng Wu, Senior Vice President | ||
| Aifeng Lyu, Executive Director | ||
| Yan Li, Joint company secretary |
HANSOH Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is HANSOH PHARMAC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.14 | |||
| Return On Asset | 0.063 | |||
| Profit Margin | 0.27 % | |||
| Operating Margin | 0.28 % | |||
| Shares Outstanding | 5.92 B | |||
| Shares Owned By Insiders | 81.92 % | |||
| Shares Owned By Institutions | 7.99 % | |||
| Price To Earning | 38.60 X | |||
| Revenue | 9.97 B | |||
| Gross Profit | 9.06 B |
Currently Active Assets on Macroaxis
Other Information on Investing in HANSOH Stock
HANSOH PHARMAC financial ratios help investors to determine whether HANSOH Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HANSOH with respect to the benefits of owning HANSOH PHARMAC security.